Amalgamated Bank Has $264,000 Stake in Nevro Corp. (NVRO)

Amalgamated Bank grew its position in Nevro Corp. (NYSE:NVRO) by 20.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,547 shares of the medical equipment provider’s stock after acquiring an additional 603 shares during the period. Amalgamated Bank’s holdings in Nevro Corp. were worth $264,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Dorsey & Whitney Trust CO LLC boosted its holdings in Nevro Corp. by 0.3% during the second quarter. Dorsey & Whitney Trust CO LLC now owns 27,871 shares of the medical equipment provider’s stock worth $2,074,000 after buying an additional 85 shares in the last quarter. Prudential Financial Inc. boosted its holdings in Nevro Corp. by 13.8% during the second quarter. Prudential Financial Inc. now owns 2,878 shares of the medical equipment provider’s stock worth $214,000 after buying an additional 350 shares in the last quarter. Legal & General Group Plc boosted its holdings in Nevro Corp. by 5.4% during the first quarter. Legal & General Group Plc now owns 8,137 shares of the medical equipment provider’s stock worth $760,000 after buying an additional 418 shares in the last quarter. Denver Investment Advisors LLC boosted its holdings in Nevro Corp. by 4.6% during the second quarter. Denver Investment Advisors LLC now owns 10,162 shares of the medical equipment provider’s stock worth $756,000 after buying an additional 445 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in Nevro Corp. by 32.4% during the first quarter. SG Americas Securities LLC now owns 2,214 shares of the medical equipment provider’s stock worth $207,000 after buying an additional 542 shares in the last quarter.

WARNING: “Amalgamated Bank Has $264,000 Stake in Nevro Corp. (NVRO)” was first reported by Markets Daily and is the property of of Markets Daily. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.themarketsdaily.com/2017/10/13/amalgamated-bank-has-264000-stake-in-nevro-corp-nvro.html.

Nevro Corp. (NYSE:NVRO) last announced its earnings results on Monday, August 7th. The medical equipment provider reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.11). Nevro Corp. had a negative return on equity of 16.25% and a negative net margin of 14.33%. The firm had revenue of $78.02 million during the quarter, compared to analyst estimates of $77.75 million. During the same quarter in the previous year, the business earned ($0.31) earnings per share. The business’s quarterly revenue was up 40.8% compared to the same quarter last year.

In other news, CFO Andrew H. Galligan sold 7,000 shares of the stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $82.31, for a total value of $576,170.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Wilfred E. Jaeger sold 79,657 shares of the stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $82.74, for a total transaction of $6,590,820.18. The disclosure for this sale can be found here. Over the last quarter, insiders sold 290,907 shares of company stock valued at $24,670,065. Corporate insiders own 12.10% of the company’s stock.

A number of equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Nevro Corp. from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. BMO Capital Markets restated a “buy” rating and set a $106.00 target price on shares of Nevro Corp. in a research report on Friday, September 1st. BidaskClub upgraded shares of Nevro Corp. from a “sell” rating to a “hold” rating in a research report on Sunday, July 16th. J P Morgan Chase & Co restated an “overweight” rating and set a $102.00 target price on shares of Nevro Corp. in a research report on Monday, July 3rd. Finally, Northland Securities set a $96.00 target price on shares of Nevro Corp. and gave the stock a “buy” rating in a research report on Thursday, June 15th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $101.25.

About Nevro Corp.

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Institutional Ownership by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply